Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04341883
Other study ID # B2019-204-01
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 13, 2019
Est. completion date December 2023

Study information

Verified date May 2022
Source Sun Yat-sen University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is an open-label, single-arm, phase II, multi-center clinical trial. Subjects can only enter this study after they meet the inclusion and exclusion criteria. All enrolled patients will receive the treatment with anti-PD-1 combined with albumin-bound paclitaxel, every 3 weeks, until progressive disease, initiation of new anti-tumour therapy, death, intolerable toxicity. Albumin-bound paclitaxel may be used for up to 6 cycles and anti-PD-1 for up to 2 years.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 27
Est. completion date December 2023
Est. primary completion date June 2022
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Voluntarily participate and have signed the informed consent form (ICF); 2. Patients histologically diagnosed with cervical cancer ; 3. Patients with advanced cervical cancer who have experienced progressive disease or relapse after receiving standard treatment (first-line chemotherapy must be included) or who are intolerant to first-line chemotherapy. 4. The radiological examination during screening confirms the presence of at least one measurable lesion evaluated according to the RECIST v1.1; 5. An Eastern Cooperative Oncology Group(ECOG) score of 0 or 1; 6. Life expectancy = 3 months; 7. Adequate hepatic, renal, heart, and hematologic functions. Absolute Neutrophil Count(ANC) = 1.5×109/L, Platelet (PLT) = 70×109/L, Hemoglobin(HGB) = 80 g/L, total bilirubin within 1.5×the upper limit of normal (ULN), and serum transaminase=2.5×Upper Limit Of Normal(ULN), serum creatine = 1.5 x Upper Limit Of Normal(ULN), creatinine clearance rate =50ml/min, International Normalized Ratio<1.5 x Upper Limit Of Normal(ULN), Urinary protein=(+)and Thyroid stimulating hormone= 1.5 x Upper Limit Of Normal(ULN). Exclusion Criteria: 1. Pathology confirmed with sarcoma components (including malignant mixed mullerian tumors, endometrial leiomyosarcoma, and endometrial stromal sarcoma); 2. Patients who have previously received albumin-bound paclitaxel or exposures to any anti-PD-1 antibody drugs; 3. Exposures to any anti-tumor drugs within 4 weeks; 4. Current or prior use of any immunosuppressive medication or systemic hormone therapy(which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid Prednisone>10mg/d)within 14 days before the first dose of anti-PD-1 antibody; 5. Any primary malignancy within 5 years (except for fully treated in situ malignant such as breast cancer, bladder cancer, cervical carcinoma in situ, cutaneous basal cell carcinoma or squamous cell carcinoma); 6. History of psychiatric drugs abuse and not be abstinent, or dysphrenia; 7. Central nervous system diseases, including uncontrollable epilepsy and symptomatic brain metastases; 8. Severe cardiovascular disease: unstable angina pectoris, myocardial infarction, grade III-IV cardiac insufficiency (NYHA standard), and peripheral vascular disease above 2 degrees within 6 months prior to enrollment; 9. Severe arrhythmia requiring drug control, QT interval >470ms; 10. Active infections such as HIV/AIDS or other serious infectious diseases; 11. Any active autoimmune disease or history of autoimmune disease (including but not limit to autoimmune hepatitis, interstitial pneumonia, hepatitis, enteritis, nephritis, hyperthyroidism, pituitary inflammation, vasculitis, uveitis) . Patients need receiving systemic hormonal therapy and/or immunosuppressive therapy (eg asthma requiring bronchodilators); 12. Receipt of live attenuated vaccination within 30 days prior to study entry; 13. Other conditions regimented at investigators' discretion.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
anti-PD-1+Albumin-Bound Paclitaxel
anti-PD-1: 200mg/3w+Albumin-bound paclitaxel: 260 mg/m2/3w.Albumin-bound paclitaxel may be used for up to 6 cycles, and anti-PD-1 for up to 2 years. Other Name: Programmed cell death 1 antibody

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate(ORR) Objective tumor response was defined as the proportion of patients whose tumor volume has been reduced to a predetermined value and can be maintained for more than 4 weeks, ie ORR=CR+PR. up to 2 years
Secondary Progression Free Survival(PFS) Progression-free survival was defined as the duration of time from study entry to time of progression, death, or the date of last contact, whichever occurs first. up to 2 years
Secondary Overall Survival(OS) Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. up to 2 years
Secondary Disease Control Rate(DCR) Disease control rate was defined as the proportion of subjects with complete response (CR) or partial response (PR) or disease stabilization (SD) in the analyzed population according to the RECIST 1.1 criteria. up to 2 years
Secondary Duration of Response(DoR) Duration of response was defined as the time when the tumor is first evaluated as CR or PR to the first assessment for progressive disease(PD) or for any cause of death. up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01764789 - Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer N/A
Completed NCT01652794 - Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Phase 1
Completed NCT01079832 - Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies Phase 2
Completed NCT00335998 - Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies Phase 1
Completed NCT00031993 - Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Recruiting NCT04974944 - First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer Phase 2
Completed NCT00941070 - Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer Phase 2
Completed NCT04380805 - A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer Phase 2
Completed NCT02849340 - Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer Phase 1/Phase 2
Completed NCT00389974 - Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Phase 2
Completed NCT00030498 - Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Phase 1
Completed NCT00031681 - 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) Phase 1
Recruiting NCT04191226 - Genetic Mutation in Recurrent Cervical Cancer
Completed NCT01676818 - Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer Phase 2
Completed NCT00004074 - Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Phase 1
Completed NCT00025233 - Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix Phase 2
Terminated NCT04230954 - Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer Phase 2
Withdrawn NCT01313104 - Colposcopy and High Resolution Anoscopy in Screening For Anal Dysplasia in Patients With Cervical, Vaginal, or Vulvar Dysplasia or Cancer N/A